Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma. Issue 6 (July 2018)

• Record Type: Journal Article
• Authors: Trafalis, Dimitrios T.; Alifieris, Constantinos E.; Kalantzis, Anastasios; Verigos, Kosmas E.; Vergadis, Chrysovalantis; Sauvage, Sébastien
• Is Part Of: Journal of immunotherapy. Volume 41:Issue 6(2018:Jul./Aug.)
• Publication Date: 2018-07
• Subjects: penile squamous cell carcinoma -- nivolumab -- immune checkpoint inhibitors -- PD-L1 -- PD-1 -- tumor-infiltrating lymphocytes; Immunotherapy -- Periodicals; Immunotherapy -- Periodicals; Neoplasms -- therapy -- Periodicals; Electronic journals; Electronic journals; 615.37
• DOI: 10.1097/CJI.0000000000000221
• Languages: English
• ISSNs: 1524-9557

Abstract

Abstract : Penile squamous cell carcinoma (PeSCC) is a rare tumor and advanced PeSCC is associated with poor survival due to the aggressiveness of the disease and lack of effective systemic therapies. We describe for the first time a case with advanced chemoradiation refractory PeSCC who had documented response to active immunotherapy with the immune checkpoint inhibitor, anti-programmed death-1 monoclonal antibody Nivolumab. The patient suffered from a poor prognosis human papillomavirus-negative PeSCC, with a somatic inactivation mutation of cyclin-dependent kinase inhibitor 2A ( CDKN2A ) gene in tumor cells, and treatment with Nivolumab resulted in a partial response to therapy and significant tumor shrinkage. Histology transitions and alterations in tumor-infiltrating cytotoxic CD8 + T-cell lymphocytes, programmed death ligand-1 expression on tumor cells and immune cells in tumor lesion biopsies pretreatment and posttreatment with Nivolumab were observed and described. In conclusion, in patients with metastatic PeSCC active immunotherapy combinations with an anti-programmed death-1/programmed death ligand-1 agent may be beneficial and further relative clinical studies are required.